197 related articles for article (PubMed ID: 18024211)
1. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.
Bonnefoi H; Potti A; Delorenzi M; Mauriac L; Campone M; Tubiana-Hulin M; Petit T; Rouanet P; Jassem J; Blot E; Becette V; Farmer P; André S; Acharya CR; Mukherjee S; Cameron D; Bergh J; Nevins JR; Iggo RD
Lancet Oncol; 2007 Dec; 8(12):1071-1078. PubMed ID: 18024211
[TBL] [Abstract][Full Text] [Related]
2. Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group.
Mavroudis D; Saloustros E; Boukovinas I; Papakotoulas P; Kakolyris S; Ziras N; Christophylakis C; Kentepozidis N; Fountzilas G; Rigas G; Varthalitis I; Kalbakis K; Agelaki S; Hatzidaki D; Georgoulias V
Br J Cancer; 2017 Jul; 117(2):164-170. PubMed ID: 28641315
[TBL] [Abstract][Full Text] [Related]
3. CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer.
Esteva FJ; Wang J; Lin F; Mejia JA; Yan K; Altundag K; Valero V; Buzdar AU; Hortobagyi GN; Symmans WF; Pusztai L
Breast Cancer Res; 2007; 9(6):R87. PubMed ID: 18086299
[TBL] [Abstract][Full Text] [Related]
4. Tissue and Serum miRNA Profile in Locally Advanced Breast Cancer (LABC) in Response to Neo-Adjuvant Chemotherapy (NAC) Treatment.
Al-Khanbashi M; Caramuta S; Alajmi AM; Al-Haddabi I; Al-Riyami M; Lui WO; Al-Moundhri MS
PLoS One; 2016; 11(4):e0152032. PubMed ID: 27064979
[TBL] [Abstract][Full Text] [Related]
5. Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial.
Ali HR; Dariush A; Thomas J; Provenzano E; Dunn J; Hiller L; Vallier AL; Abraham J; Piper T; Bartlett JMS; Cameron DA; Hayward L; Brenton JD; Pharoah PDP; Irwin MJ; Walton NA; Earl HM; Caldas C
Ann Oncol; 2017 Aug; 28(8):1832-1835. PubMed ID: 28525534
[TBL] [Abstract][Full Text] [Related]
6. Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer.
Ali HR; Dariush A; Provenzano E; Bardwell H; Abraham JE; Iddawela M; Vallier AL; Hiller L; Dunn JA; Bowden SJ; Hickish T; McAdam K; Houston S; Irwin MJ; Pharoah PD; Brenton JD; Walton NA; Earl HM; Caldas C
Breast Cancer Res; 2016 Feb; 18(1):21. PubMed ID: 26882907
[TBL] [Abstract][Full Text] [Related]
7. Coagulation factor V in breast cancer: a p53-regulated tumor suppressor and predictive marker for treatment response to chemotherapy.
Lind SM; Sletten M; Hellenes M; Mathelier A; Tekpli X; Tinholt M; Iversen N
J Thromb Haemost; 2024 Jun; 22(6):1569-1582. PubMed ID: 38382738
[TBL] [Abstract][Full Text] [Related]
8. The prediction of pCR and chemosensitivity for breast cancer patients using DLG3, RADL and Pathomics signatures based on machine learning and deep learning.
Jiang C; Zhang X; Qu T; Yang X; Xiu Y; Yu X; Zhang S; Qiao K; Meng H; Li X; Huang Y
Transl Oncol; 2024 May; 46():101985. PubMed ID: 38805774
[TBL] [Abstract][Full Text] [Related]
9. Fuzzy logic selection as a new reliable tool to identify molecular grade signatures in breast cancer--the INNODIAG study.
Kempowsky-Hamon T; Valle C; Lacroix-Triki M; Hedjazi L; Trouilh L; Lamarre S; Labourdette D; Roger L; Mhamdi L; Dalenc F; Filleron T; Favre G; François JM; Le Lann MV; Anton-Leberre V
BMC Med Genomics; 2015 Feb; 8():3. PubMed ID: 25888889
[TBL] [Abstract][Full Text] [Related]
10. High Expression of Pyruvate Kinase M2 is Associated with Chemosensitivity to Epirubicin and 5-Fluorouracil in Breast Cancer.
Lin Y; Lv F; Liu F; Guo X; Fan Y; Gu F; Gu J; Fu L
J Cancer; 2015; 6(11):1130-9. PubMed ID: 26516361
[TBL] [Abstract][Full Text] [Related]
11. Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer.
Ein-Dor L; Zuk O; Domany E
Proc Natl Acad Sci U S A; 2006 Apr; 103(15):5923-8. PubMed ID: 16585533
[TBL] [Abstract][Full Text] [Related]
12. Multi-omic machine learning predictor of breast cancer therapy response.
Sammut SJ; Crispin-Ortuzar M; Chin SF; Provenzano E; Bardwell HA; Ma W; Cope W; Dariush A; Dawson SJ; Abraham JE; Dunn J; Hiller L; Thomas J; Cameron DA; Bartlett JMS; Hayward L; Pharoah PD; Markowetz F; Rueda OM; Earl HM; Caldas C
Nature; 2022 Jan; 601(7894):623-629. PubMed ID: 34875674
[TBL] [Abstract][Full Text] [Related]
13. Clinical Biomarkers of Tumour Radiosensitivity and Predicting Benefit from Radiotherapy: A Systematic Review.
Bleaney CW; Abdelaal H; Reardon M; Anandadas C; Hoskin P; Choudhury A; Forker L
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38792019
[TBL] [Abstract][Full Text] [Related]
14. Using Breast Cancer Gene Expression Signatures in Clinical Practice: Unsolved Issues, Ongoing Trials and Future Perspectives.
Varnier R; Sajous C; de Talhouet S; Smentek C; Péron J; You B; Reverdy T; Freyer G
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638325
[TBL] [Abstract][Full Text] [Related]
15. Retraction--Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.
Bonnefoi H; Potti A; Delorenzi M; Mauriac L; Campone M; Tubiana-Hulin M; Petit T; Rouanet P; Jassem J; Blot E; Becette V; Farmer P; André S; Acharya CR; Mukherjee S; Cameron D; Bergh J; Nevins JR; Iggo RD
Lancet Oncol; 2011 Feb; 12(2):116. PubMed ID: 21277543
[No Abstract] [Full Text] [Related]
16. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.
Hatzis C; Pusztai L; Valero V; Booser DJ; Esserman L; Lluch A; Vidaurre T; Holmes F; Souchon E; Wang H; Martin M; Cotrina J; Gomez H; Hubbard R; Chacón JI; Ferrer-Lozano J; Dyer R; Buxton M; Gong Y; Wu Y; Ibrahim N; Andreopoulou E; Ueno NT; Hunt K; Yang W; Nazario A; DeMichele A; O'Shaughnessy J; Hortobagyi GN; Symmans WF
JAMA; 2011 May; 305(18):1873-81. PubMed ID: 21558518
[TBL] [Abstract][Full Text] [Related]
17. Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization.
Kao KJ; Chang KM; Hsu HC; Huang AT
BMC Cancer; 2011 Apr; 11():143. PubMed ID: 21501481
[TBL] [Abstract][Full Text] [Related]
18. Multifactorial approach to predicting resistance to anthracyclines.
Desmedt C; Di Leo A; de Azambuja E; Larsimont D; Haibe-Kains B; Selleslags J; Delaloge S; Duhem C; Kains JP; Carly B; Maerevoet M; Vindevoghel A; Rouas G; Lallemand F; Durbecq V; Cardoso F; Salgado R; Rovere R; Bontempi G; Michiels S; Buyse M; Nogaret JM; Qi Y; Symmans F; Pusztai L; D'Hondt V; Piccart-Gebhart M; Sotiriou C
J Clin Oncol; 2011 Apr; 29(12):1578-86. PubMed ID: 21422418
[TBL] [Abstract][Full Text] [Related]
19. Retraction: Genomic signatures to guide the use of chemotherapeutics.
Potti A; Dressman HK; Bild A; Riedel RF; Chan G; Sayer R; Cragun J; Cottrill H; Kelley MJ; Petersen R; Harpole D; Marks J; Berchuck A; Ginsburg GS; Febbo P; Lancaster J; Nevins JR
Nat Med; 2011 Jan; 17(1):135. PubMed ID: 21217686
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
